CareDx, Inc. will report its financial results for the second quarter of 2026 after the market closes on July 30, 2026. The precision medicine diagnostics company, focused on transplant, specialty oncology, and cell therapy, will host a conference call the same day to discuss its quarterly performance.

The earnings call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors can access a live and archived webcast of the event through the Events & Presentations section of the CareDx Investor Relations website. Telephone participants must register online in advance to receive a dial-in number and a unique PIN.

CareDx specializes in non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions aimed at improving patient outcomes in its target medical fields.

Key Event Details

Investors seeking further information or wishing to participate in the live call can visit the company's investor relations portal.

CareDx, Inc. has completed its acquisition of Naveris, extending its leadership into high-growth specialty oncology. The transaction, which was initially announced in April 2026, adds Naveris’s lead product, NavDx, to CareDx’s portfolio of precision diagnostic testing services. This strategic move expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy.

NavDx is a blood-based test designed to detect and monitor viral-mediated cancers, including human papillomavirus (HPV)-associated head and neck and anal cancers. It covers the entire patient journey from diagnosis through post-treatment molecular residual disease (MRD) surveillance. Notably, NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.

The commercial performance of NavDx has been strong, with over 130,000 tests reported to date. The test secured Medicare coverage in 2023 and carries an ADLT Medicare reimbursement rate of $1,800. In 2025, Naveris generated approximately $35 million in revenue, representing a year-over-year increase of more than 100%.

Financial Integration and Market Impact

Beginning in the third quarter of 2026, Naveris will be included in CareDx’s consolidated financial results. The integration aligns with CareDx’s growth model of commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease.

John Hanna, President and Chief Executive Officer of CareDx, emphasized the strategic fit of the acquisition. He stated that NavDx fits CareDx’s growth model precisely and expressed confidence that the company has the platform and focus to scale the test. Hanna expects NavDx to be a meaningful contributor to CareDx’s growth from day one.

CareDx is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the company aims to improve patient outcomes.